MedTrace Logo

XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer

NCT01777945 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 46

Last updated 2016-08-19

Study results available
· View outcomes & findings →

Summary

This multicenter observational study will evaluate the efficacy and safety of Xeloda (capecitabine) in combination with docetaxel in first-line therapy in participants with HER2-negative metastatic breast cancer. Participants will be followed for approximately 6 months of treatment.

Conditions

Interventions

DRUG

capecitabine

Participants received capecitabine according to individualized physician-prescribed regimen.

DRUG

docetaxel

Participants received docetaxel according to individualized physician-prescribed regimens.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01777945 on ClinicalTrials.gov